Drug development, which includes clinical trials, is a lengthy and expensive process that could significantly benefit from predictive modeling and in silico testing. Additionally, current treatments were designed based on the average patient using the "one size fits all" protocol. Therefore, they can be effective on some patients but not for others. There is an urgent need to replace such generalized approaches with personalized and predictive strategies that capture and analyze human diversity and variation at a resolution sufficient to identify and clinically validate personalized treatment paradigms. Utilization of heterogenous datasets, such as Electronic Health Records (EHRs), to build synthetic populations of patients and personalized, predictive models of response to therapy holds enormous promise in precipitating a revolution in precision medicine for IBD. In silico trials can be designed to include multi-modal data sources, including clinical trial data at the individual and aggregated levels, pre-clinical data from animal studies, as well as data from EHR. In silico clinical trials can help inform the design of clinical trials and make prediction at the population and individual level to increase the chances of success. This chapter discusses pioneering work on the use of in silico clinical trials to accelerate the development of new drugs.
All Science Journal Classification (ASJC) codes
- General Medicine
- General Immunology and Microbiology
- General Computer Science
- General Agricultural and Biological Sciences
- General Biochemistry, Genetics and Molecular Biology